Home › Compare › COLRF vs ABBV
COLRF yields 3.20% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, COLRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of COLRF + ABBV for your $10,000?
China Medical & HealthCare Group Limited, an investment holding company, primarily operates hospitals in the People's Republic of China, Australia, and the Philippines. It operates through six segments: Healthcare, Eldercare, Property Development, Property Investment, Financial Services, and Securities Trading and Investments. The company is also involved in the property development of independent living units; and project management of health campus with a focus on elderly care and retirement community comprising elderly nursing homes, service apartments, and independent living units, as well as a shopping mall, retail shops, and club hall facilities. In addition, it develops and sells properties and land; leases residential and office properties; and provides money lending and healthcare services. Further, the company is involved in trading of medical equipment and related supplies; and securities listed in overseas exchange. The company was formerly known as COL Capital Limited and changed its name to China Medical & HealthCare Group Limited in February 2016. China Medical & HealthCare Group Limited was incorporated in 1990 and is headquartered in Wanchai, Hong Kong.
Full COLRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.